Assessment of Needs
The IAS–USA offers this introductory activity on the evolving challenges of managing HIV disease as part of a nationwide continuing medical education (CME) effort for physicians. This webinar is designed for HIV or infectious disease fellows, residents, and practitioners who are new to the field of HIV research and management. It will describe the core principles of HIV management, including epidemiology, mechanisms of action of existing drugs, initial antiretroviral regimens, and drug resistance. This webinar will also be useful to experienced clinicians who seek a review of these core principles.
On completion of this webinar, learners will be able to:
- Summarize events of early HIV infection
- List the sequence of laboratory markers following HIV acquisition
- Describe basic mechanisms of antiretroviral therapy
- Select antiretroviral therapy in patients who:
- Are starting initial therapy
- Have persistently low-level viremia
- Are pregnant or considering pregnancy
- Are experiencing virologic failure / resistance
Who Should Attend
This webinar is designed for clinical decision makers who are new to or actively involved in HIV care and research. It is also relevant for registered nurses, PharmDs, and other health professionals.
Individual registration is required, even if you are viewing as a group, in order to receive CME credit or a certificate of participation.
Registration closes on Monday, June 17, 2019, 4:00 PM (PT).
Certificates will be available after the completion of the evaluation and claim form.
For more information or questions, please contact the registration department at email@example.com or 415-544-9400.
Conflicts of Interest
In the interest of maintaining the independence of its CME activities, and in accordance with the policies of the Accreditation Council for Continuing Medical Education (ACCME), the IAS–USA requires all persons with control of content (eg, faculty, IAS–USA Board members, and program staff) to disclose any financial relationships that they or their spouses or partners have had with commercial companies within the past 12 months. Any real or apparent conflicts of interest of those parties are resolved prior to the CME activity being delivered. Individuals who refuse to disclose financial interests may not participate in an IAS–USA CME activity.
The ACCME defines a commercial interest as “any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests – unless the provider of clinical service is owned, or controlled by, an ACCME-defined commercial interest.”
Dr Saag has received research grants and support awarded to his institution from Gilead Sciences, Inc, Merck, and ViiV Healthcare. (Updated 06/18/19)
Dr Spach has no relevant financial affiliations to disclose. (Updated 06/18/19)
CME Planner and Reviewer
Ms Jacobsen has no relevant financial affiliations to disclose. (Updated 06/18/19)
Continuing Education Credits
The International Antiviral Society–USA (IAS–USA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The IAS–USA designates this live activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Educational Review Systems is an approved approver of continuing nursing education by the Alabama State Nursing Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation. Provider # 5-115. This program is approved for 1.50 hours of continuing nursing education.
Educational Review Systems is also approved for nursing continuing education by the state of California, the state of Florida and the District of Columbia.
This program is approved for 1.50 hours of pharmacotherapy credit.
Educational Review Systems is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This program is approved for 1.50 hours (0.15 CEUs) of continuing pharmacy education credit. Proof of participation will be posted to your NABP CPE profile within 4 to 6 weeks to participants who have successfully completed the post-test. Participants must participate in the entire presentation and complete the course evaluation to receive continuing pharmacy education credit.
UAN # 0761-9999-19-037-L02-P
This activity is part of the IAS–USA national educational effort that is funded, in part, by charitable contributions from commercial companies. Per IAS–USA policy, any effort that uses commercial grants must receive grants from several companies with competing products. Funds are pooled and distributed to activities at the sole discretion of the IAS–USA. Grantors have no input into any activity, including its content, development, or selection of topics or speakers. Generous support for this activity has been received from the following contributors.
Gilead Sciences, Inc.
Merck & Co, Inc.
Additional support has been provided by
Frequently Asked Questions
View our list of FAQs about attending a webinar.
Please contact the registration department at firstname.lastname@example.org or 415-544-9400.